CESSATION THERAPEUTICS, INC.

Profile

Company Names

CESSATION THERAPEUTICS, INC.

Addresses

12200 STEMMONS FREEWAY, SUITE 100, DALLAS, TX 75234

3031 TISCH WAY, STE. 505, SAN JOSE, CA 95128

Phone Numbers

408-479-7843

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2022

State Incorporated:

DELAWARE

Total Amount Raised:

$6,755,000.00

Number of Funding Rounds:

2
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
2
2024-03-29 
$1,000,000.00 
$1,000,000.00 
$0.00 
Debt 
1
2022-05-02 
$5,755,000.00 
$10,000,000.00 
$4,245,000.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
ANDREW 
 
BARRETT 
EXECUTIVE OFFICER
CESSATION THERAPEUTICS, INC.
DANIEL 
 
FINE 
DIRECTOR
TAMARAC INC   |  GLASS U, LLC   |  ANI ENERGY, LLC   |  FLOAT FINANCIAL, LLC   |  CESSATION THERAPEUTICS, INC.
DAVID 
 
GENECOV 
DIRECTOR
FOREST PARK MEDICAL CENTER AT SOUTHLAKE, LLC   |  DIALECTIC THERAPEUTICS, INC.   |  CERSCI THERAPEUTICS INC.   |  CESSATION THERAPEUTICS, INC.
JOHN 
 
HARKEY 
DIRECTOR, EXECUTIVE OFFICER
EMISPHERE TECHNOLOGIES INC   |  LITTLE SISTER PARTNERS, LLC   |  CESSATION THERAPEUTICS, INC.
MARK 
 
PEARSON 
DIRECTOR, EXECUTIVE OFFICER
ARCUS ZENSEN FUND   |  ARCUS GENSEKI FUND   |  ARCUS JAPAN VALUE FUND   |  THEOREMDX INC.   |  ASHTON OAK HOMES (BROADWAY) INVESTORS, LLC   |  CESSATION THERAPEUTICS, INC.   |  ASHTON OAK HOMES (BLACK LOCUST) INVESTORS, LLC
ERIC 
 
RASMUSSEN 
EXECUTIVE OFFICER
SPACIOUS SKIES WALNUT GROVE, LLC   |  CESSATION THERAPEUTICS, INC.   |  ELECTRUM DISCOVERY CORP.
JAY 
 
SHEPARD 
DIRECTOR
NEXTWAVE PHARMACEUTICALS INC   |  BULLET BIOTECHNOLOGY, INC.   |  VERSARTIS, INC.   |  NEURORECOVERY TECHNOLOGIES, INC.   |  INOVIO PHARMACEUTICALS, INC.   |  CESSATION THERAPEUTICS, INC.
SHARON 
 
TETLOW 
DIRECTOR
4D MOLECULAR THERAPEUTICS INC   |  DICE MOLECULES HOLDINGS, LLC   |  CESSATION THERAPEUTICS, INC.   |  SIREN BIOTECHNOLOGY, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2024-04-03
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2024-03-29 
2022-05-11
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2022-05-02 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#